2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3513 Integrated multi-omics analysis reveals epigenetic remodeling and oxidative phosphorylation activation following DNMT3B loss in mantle cell lymphoma

Xiaoyue Gao, MS, Nguyet Minh Hoang, BS2, Yunxia Liu, PhD3, Qinyu Ni, MS4, Lixin Rui, PhD5
1 University of Wisconsin-Madison, Madison, United States
2 University of Wisconsin-Madison, Madison, United States
3 University of Wisconsin-Madison, Madison, United States
4 University of Wisconsin-Madison, Madison, United States
5 University of Wisconsin-Madison, Madison, United States

DNA methylation is a fundamental epigenetic mechanism regulating gene expression. Although altered expression of DNA methyltransferases (DNMTs) has been reported in lymphoma, the biological function of DNMT3B in mantle cell lymphoma (MCL) remains poorly understood.

To characterize DNMT3B expression in MCL, we performed immunohistochemical staining on a tissue microarray containing 58 MCL tumors and 12 normal lymphoid tissues (6 lymph nodes and 6 tonsils). DNMT3B protein expression was significantly reduced in MCL compared with normal tissues, consistent with multiple public transcriptomic datasets (GSE32018, GSE45717, and GSE303064). Kaplan–Meier analysis further demonstrated that lower DNMT3B expression was associated with inferior patient survival. Functional studies using doxycycline-inducible DNMT3B knockout and overexpression cell lines, together with pharmacologic inhibition using Nanaomycin A, demonstrated that DNMT3B depletion or inhibition promoted MCL cell proliferation, whereas DNMT3B overexpression suppressed cell growth, supporting a tumor-suppressive role for DNMT3B.

To investigate the underlying mechanism, we performed integrated RNA sequencing, DNMT3B ChIP sequencing, and Oxford Nanopore whole-genome methylation sequencing. Gene set enrichment analysis identified significant activation of oxidative phosphorylation (OXPHOS) and MYC target pathways following DNMT3B loss. Oxford Nanopore sequencing demonstrated that DNMT3B depletion did not substantially alter global CpG methylation levels but induced extensive locus-specific methylation remodeling, including both hypo- and hypermethylated regions distributed predominantly within intergenic and intronic regions, consistent with the genomic distribution of DNMT3B binding sites. Differentially methylated regions were identified in genes associated with oxidative phosphorylation, suggesting that DNMT3B regulates metabolic pathways through epigenetic remodeling rather than global DNA hypomethylation. In addition, differential methylation was observed at regulatory regions of DNMT3A, MYC, and TET1, suggesting that DNMT3B loss broadly remodels the epigenetic landscape beyond genes directly involved in oxidative phosphorylation.

Functional analyses further implicated DNMT3B in mitochondrial metabolism. DNMT3B knockout and catalytic inhibition increased MitoTracker Deep Red staining, while preliminary Seahorse analysis suggested reduced oxygen consumption following DNMT3B overexpression. These complementary findings are consistent with the transcriptomic enrichment of oxidative phosphorylation pathways following DNMT3B loss.

Collectively, our findings identify DNMT3B as a tumor suppressor in MCL and suggest that loss of DNMT3B promotes metabolic reprogramming through locus-specific epigenetic remodeling, leading to activation of oxidative phosphorylation pathways.

Xiaoyue Gao, MS: No relevant conflicts of interest to declare.